Wall Street analysts covering X4 Pharmaceuticals maintain consensus Strong Buy recommendations, pointing to significant commercial upside for its rare disease portfolio and favorable long-term target prices. Nonetheless, biotech investments involve high risks, including clinical trial outcomes and capital requirements. What is your target investment horizon and portfolio risk profile? Reviewing financial statements and consulting a licensed financial advisor is crucial before investing.